The effect of curcumin on diabetic sensorimotor polyneuropathy

Investigating the effect of curcumin compared to conventional treatment on the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230829059301N1

Enrollment

Registered

2024-03-22

Start date

2024-03-19

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic sensorimotor polyneuropathy. Other specified polyneuropathies

Interventions

Intervention 1: Intervention group: In addition to the usual treatment, this group receives 80 mg cocumin capsules daily for two months. Intervention 2: Control group: This group only receives the usu

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with diabetic sensorimotor polyneuropathy caused by type 2 diabetes A score of at least 6 in Tonto Clinical Neuropathy Score At least 18 years old and at least 70 years old

Exclusion criteria

Exclusion criteria: Patients who have sensorimotor polyneuropathy due to other diseases Patients with hypothyroidism Those who smoke Body mass index more than 34.9 Female patients who become pregnant Being during breastfeeding Patients who have cancer (such as pancreas, digestive system, kidney, etc.)

Design outcomes

Primary

Measure	Time frame
Toronto Clinical Neuropathy Score. Timepoint: At the beginning and end of the study. Method of measurement: By medical doctor.;FASTING BLOOD SUGAR. Timepoint: at the beginning of the study. Method of measurement: BY LABORATORY.;LDL. Timepoint: at the beginning of the study. Method of measurement: BY LABORATORY.;Blood pressure. Timepoint: at the beginning of the study. Method of measurement: Mercury sphygmomanometer.;Body mass index. Timepoint: at the beginning of the study. Method of measurement: Measuring the ratio of body weight (in kilograms) to the square of height (in meters)Community Verified icon.;Complete blood count test. Timepoint: at the beginning of the study. Method of measurement: LABORATORY TEST.;Urine analysis. Timepoint: at the beginning of the study. Method of measurement: by the laboratory test.;Creatinine and blood urea test. Timepoint: at the beginning of the study. Method of measurement: by the laboratory test.;Blood TSH level test. Timepoint: at the beginning of the study. Method of measurement: by the laboratory test.;HB1AC. Timepoint: AT THE BEGINNING OF THE STUDY. Method of measurement: BY THE LABORATORY TEST.;HDL. Timepoint: AT THE BEGINNING OFTHE STUDY. Method of measurement: BY THE LABORATORY TEST.;TOTAL CHOLESTROL. Timepoint: AT THE BEGINNING OF THE SUDY. Method of measurement: BY THE LABORATORY TEST.;TG. Timepoint: AT THE BEGINNING OF THE SUDY. Method of measurement: BY THE LABORATORY TEST.;RANDOM URINE ALBUMIN CERATININE RATIO. Timepoint: AT THE BEGINNING OF THE STUDY. Method of measurement: BY THE LABORATORY TEST.	—

Measure

Time frame

Toronto Clinical Neuropathy Score. Timepoint: At the beginning and end of the study. Method of measurement: By medical doctor.;FASTING BLOOD SUGAR. Timepoint: at the beginning of the study. Method of measurement: BY LABORATORY.;LDL. Timepoint: at the beginning of the study. Method of measurement: BY LABORATORY.;Blood pressure. Timepoint: at the beginning of the study. Method of measurement: Mercury sphygmomanometer.;Body mass index. Timepoint: at the beginning of the study. Method of measurement: Measuring the ratio of body weight (in kilograms) to the square of height (in meters)Community Verified icon.;Complete blood count test. Timepoint: at the beginning of the study. Method of measurement: LABORATORY TEST.;Urine analysis. Timepoint: at the beginning of the study. Method of measurement: by the laboratory test.;Creatinine and blood urea test. Timepoint: at the beginning of the study. Method of measurement: by the laboratory test.;Blood TSH level test. Timepoint: at the beginning of the study. Method of measurement: by the laboratory test.;HB1AC. Timepoint: AT THE BEGINNING OF THE STUDY. Method of measurement: BY THE LABORATORY TEST.;HDL. Timepoint: AT THE BEGINNING OFTHE STUDY. Method of measurement: BY THE LABORATORY TEST.;TOTAL CHOLESTROL. Timepoint: AT THE BEGINNING OF THE SUDY. Method of measurement: BY THE LABORATORY TEST.;TG. Timepoint: AT THE BEGINNING OF THE SUDY. Method of measurement: BY THE LABORATORY TEST.;RANDOM URINE ALBUMIN CERATININE RATIO. Timepoint: AT THE BEGINNING OF THE STUDY. Method of measurement: BY THE LABORATORY TEST.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Moslemi

Semnan University of Medical Sciences

alireza.moslemi91@gmail.com+98 23 3142 0000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026